DISC MEDICINE INC (IRON) Stock Price & Overview

NASDAQ:IRON • US2546041011

63.75 USD
-0.48 (-0.75%)
Last: Mar 10, 2026, 12:19 PM

The current stock price of IRON is 63.75 USD. Today IRON is down by -0.75%. In the past month the price decreased by -19.43%. In the past year, price increased by 25.89%.

IRON Key Statistics

52-Week Range30.82 - 99.5
Current IRON stock price positioned within its 52-week range.
1-Month Range40.0001 - 79.8
Current IRON stock price positioned within its 1-month range.
Market Cap
2.433B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-6.01
Dividend Yield
N/A

IRON Stock Performance

Today
-0.75%
1 Week
-3.47%
1 Month
-19.43%
3 Months
-30.07%
Longer-term
6 Months +7.37%
1 Year +25.89%
2 Years +3.16%
3 Years +203.11%
5 Years N/A
10 Years N/A

IRON Stock Chart

DISC MEDICINE INC / IRON Daily stock chart

IRON Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to IRON. When comparing the yearly performance of all stocks, IRON is a bad performer in the overall market: 69.07% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
IRON Full Technical Analysis Report

IRON Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IRON. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IRON Full Fundamental Analysis Report

IRON Earnings

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.64
Revenue Reported
EPS Surprise 7.82%
Revenue Surprise %
IRON Earnings History

IRON Forecast & Estimates

19 analysts have analysed IRON and the average price target is 104.64 USD. This implies a price increase of 64.13% is expected in the next year compared to the current price of 63.75.


Analysts
Analysts86.32
Price Target104.64 (64.14%)
EPS Next Y-20.54%
Revenue Next YearN/A
IRON Forecast & Estimates

IRON Groups

Sector & Classification

IRON Financial Highlights

Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -6.01. The EPS decreased by -50.63% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-212.18M
Industry RankSector Rank
PM (TTM) N/A
ROA -26.3%
ROE -28.68%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%-67.35%
Sales Q2Q%N/A
EPS 1Y (TTM)-50.63%
Revenue 1Y (TTM)N/A
IRON financials

IRON Ownership

Ownership
Inst Owners96.15%
Shares38.16M
Float31.84M
Ins Owners0.68%
Short Float %10.82%
Short Ratio4.46
IRON Ownership

IRON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.31402.17B
AMGN AMGEN INC16.54203.213B
GILD GILEAD SCIENCES INC16.83182.029B
VRTX VERTEX PHARMACEUTICALS INC25.96117.075B
REGN REGENERON PHARMACEUTICALS16.6582.631B
ALNY ALNYLAM PHARMACEUTICALS INC43.3242.915B
INSM INSMED INC N/A30.852B
NTRA NATERA INC N/A29.086B
BIIB BIOGEN INC11.7927.626B
UTHR UNITED THERAPEUTICS CORP18.2423.193B
MRNA MODERNA INC N/A22.014B
EXAS EXACT SCIENCES CORP341.0219.797B
RVMD REVOLUTION MEDICINES INC N/A19.775B

About IRON

Company Profile

IRON logo image Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Company Info

IPO: 2020-08-12

DISC MEDICINE INC

321 Arsenal Street, Suite 101

Watertown MASSACHUSETTS US

Employees: 155

IRON Company Website

IRON Investor Relations

Phone: 16176749274

DISC MEDICINE INC / IRON FAQ

Can you describe the business of DISC MEDICINE INC?

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.


What is the stock price of DISC MEDICINE INC today?

The current stock price of IRON is 63.75 USD. The price decreased by -0.75% in the last trading session.


Does IRON stock pay dividends?

IRON does not pay a dividend.


What is the ChartMill rating of DISC MEDICINE INC stock?

IRON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What do analysts say about DISC MEDICINE INC (IRON) stock?

19 analysts have analysed IRON and the average price target is 104.64 USD. This implies a price increase of 64.13% is expected in the next year compared to the current price of 63.75.


How is the valuation of DISC MEDICINE INC (IRON) based on its PE ratio?

DISC MEDICINE INC (IRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.01).


What is DISC MEDICINE INC worth?

DISC MEDICINE INC (IRON) has a market capitalization of 2.43B USD. This makes IRON a Mid Cap stock.